Eaton Capital

Eton Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of innovative treatments for rare diseases, particularly in the pediatric population. The company has a diverse portfolio of FDA-approved products, including Alkindi Sprinkle for adrenocortical insufficiency and Carglumic Acid for hyperammonemia. Eton's business model centers on acquiring and advancing late-stage, low-risk drug candidates that address significant unmet needs in orphan markets. By leveraging its commercial infrastructure and regulatory expertise, Eton aims to provide improved therapeutic options through optimized delivery systems and dosing formulations. The company maintains an active pipeline of candidates in various stages of clinical and regulatory development.